1月7日，威高血净跌2.17%，成交额1.53亿元。两融数据显示，当日威高血净获融资买入额1834.67万 元，融资偿还1608.79万元，融资净买入225.88万元。截至1月7日，威高血净融资融券余额合计1.46亿 元。 融资方面，威高血净当日融资买入1834.67万元。当前融资余额1.45亿元，占流通市值的9.00%。 截至9月30日，威高血净股东户数2.48万，较上期减少20.95%；人均流通股1535股，较上期增加 26.51%。2025年1月-9月，威高血净实现营业收入27.36亿元，同比增长3.45%；归母净利润3.41亿元，同 比增长7.92%。 分红方面，威高血净A股上市后累计派现6582.13万元。 责任编辑：小浪快报 融券方面，威高血净1月7日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00元； 融券余量6300.00股，融券余额25.87万元。 资料显示，山东威高血液净化制品股份有限公司位于山东省威海火炬高技术产业开发区威高西路7号， 成立日期2004年12月27日，上市日期2025年5月19日，公司主营业务涉及血液净化医用制品的研发、生 产和销售。主营业务收入 ...

中金发布研报称，考虑上游拓展仍需一定时间而普耗集采压力略高于1H25预期，下调威高股份 (01066)25/26年净利润7%/7%至19.89/21.83亿元，引入27年净利润23.48亿元，当前股价对应26/27年P/E 为9.9/8.9x，考虑板块估值中枢上行，该行维持目标价6.40港元和跑赢行业评级不变，对应26/27年P/E为 12.1/11.3x，隐含22.4%上行空间。 中金主要观点如下： 2026年1月5日，威高股份公告与威高血净（603014）交易进展，换股交易对价合理，公司将控股威高血 净 风险提示：集采降价，新品推广不及预期，国际化不及预期，竞争格局恶化。 威高普瑞业绩承诺较为合理谨慎 威高股份承诺普瑞将在26-28年达到净利润分别为6.39/7.20/7.84亿元，复合增速10.7%。如交易实施完毕 的时间延后至2027年，则普瑞27-29年承诺净利润分别为7.20/7.84/8.45亿元，复合增速8.3%。 血净和普瑞具有协同效应，共同拓展生物制药上游大赛道 威高血净聚焦血液透析和腹膜透析的耗材和设备，具备透析膜术，已有滤器产品。威高普瑞专注于预灌 封给药系统及自动安全给药系统等面向疫 ...

Core Viewpoint - The stock of Weigao Blood Purification experienced a decline of 2.00% on January 7, 2025, with a trading price of 41.14 yuan per share and a market capitalization of 17.186 billion yuan. The company has shown a year-to-date stock price increase of 3.81% and a recent five-day increase of 2.49% [1]. Group 1: Financial Performance - For the period from January to September 2025, Weigao Blood Purification achieved a revenue of 2.736 billion yuan, representing a year-on-year growth of 3.45%. The net profit attributable to shareholders was 341 million yuan, reflecting a year-on-year increase of 7.92% [2]. - The company has distributed a total of 65.8213 million yuan in dividends since its A-share listing [3]. Group 2: Stock and Market Activity - As of January 7, 2025, the stock's trading volume was 76.4939 million yuan, with a turnover rate of 4.70%. The net outflow of main funds was 5.7063 million yuan, with large orders accounting for 16.12% of purchases and 23.57% of sales [1]. - The number of shareholders decreased by 20.95% to 24,800, while the average circulating shares per person increased by 26.51% to 1,535 shares [2]. Group 3: Company Overview - Weigao Blood Purification, established on December 27, 2004, is located in Weihai, Shandong Province. The company specializes in the research, production, and sales of blood purification medical products. Its revenue composition includes consumables (77.55%), equipment (18.25%), and other categories (4.20%) [1].

绑定三年业绩承诺 1月5日晚，国内血液净化领域龙头企业山东威高血液净化制品股份有限公司（以下简称"威高血净 （603014）"）发布重大资产重组草案，拟以发行股份方式，作价85.11亿元收购山东威高普瑞医药包装 有限公司（以下简称"威高普瑞"）100%股权。根据重组草案，本次交易的标的公司威高普瑞，与上市 公司威高血净同属一个实际控制人陈学利，且交易完成后上市公司实际控制人仍为陈学利，因此本次资 产重组为同一控制下的资产整合，通过本次交易，威高血净也将拓展至医药包材赛道。 收购"自家"资产 根据交易草案，本次交易标的威高普瑞100%股权的评估值为85.11亿元，较其账面净资产增值约 192.90%。交易对价将全部以发行股份方式支付，发行价格为31.29元/股。交易完成后，威高普瑞将成 为上市公司的全资子公司。 本次收购是威高体系内部的资源整合。草案显示，本次交易对方包括山东威高集团医用高分子制品股份 有限公司（以下简称"威高股份"）、威海盛熙企业管理咨询中心（有限合伙）（以下简称"威海盛熙"） 和威海瑞明企业管理咨询合伙企业（有限合伙）（以下简称"威海瑞明"），三者均为上市公司实际控制 人陈学利所控制的企业。 ...

Core Viewpoint - Weigao Blood Purification plans to acquire 100% equity of Weigao Purui for a total transaction amount of 8.511 billion yuan, which will enhance its product line into pharmaceutical packaging materials and expand its market presence in the biopharmaceutical upstream business [1][2]. Group 1: Acquisition Details - The acquisition will be executed through a share issuance priced at 31.29 yuan per share, with approximately 272 million shares to be issued, representing 39.43% of the total share capital post-issuance [1]. - After the transaction, Weigao Blood Purification's controlling shareholder will change from Weigao Group to Weigao Co., which will hold an 84.36% stake, maintaining the actual controller as Chen Xueli [1]. Group 2: Financial Performance of Weigao Purui - Weigao Purui has a strong market position, holding over 50% of the domestic market share for pre-filled products from 2022 to 2024, ranking first in the industry [2]. - The company has demonstrated robust profitability, with projected revenues of 1.426 billion yuan, 1.684 billion yuan, and 939 million yuan for 2023 to the first half of 2025, and net profits of 490 million yuan, 585 million yuan, and 327 million yuan for the same periods [2]. Group 3: Weigao Blood Purification's Business Overview - Weigao Blood Purification is a leading enterprise in the blood purification field, focusing on the R&D and production of blood dialysis devices and related products [2]. - The company has shown steady performance, with total revenue of 2.736 billion yuan for the first three quarters of 2025, reflecting a year-on-year growth of 3.45%, and a net profit of 341 million yuan, up 7.92%, with a gross margin of 40.69% [2]. Group 4: Future Projections - Following the acquisition, Weigao Blood Purification's profitability is expected to improve significantly, with projected increases in revenue and net profit of 51.56% and 142.57%, respectively, for the first three quarters of 2025, and total assets anticipated to reach 12.044 billion yuan [2].

Core Viewpoint - Weigao Blood Purification announced plans to acquire 100% equity of Weigao Purui for approximately 8.511 billion yuan through a share issuance, expanding its business into the development, production, and sales of pre-filled drug delivery systems and automatic safety drug delivery systems [1] Group 1 - The transaction involves purchasing shares from three parties: Weigao Co., Weihai Shengxi, and Weihai Ruiming [1] - The share issuance price is set at 31.29 yuan per share [1] - Upon completion of the transaction, Weigao Purui will become a wholly-owned subsidiary of Weigao Blood Purification [1]

南方财经1月6日电，威高血净（603014.SH）近日披露发行股份购买资产暨关联交易方案，拟通过发行 股份方式收购威高股份、威海盛熙、威海瑞明合计持有的威高普瑞100%股权，交易作价85.11亿元。本 次发行价格为31.29元/股，对应发行股份数量约2.72亿股，占发行后公司总股本的39.43%。交易完成 后，公司控股股东将由威高集团变更为威高股份，实际控制人仍为陈学利，控制权未发生变更，公司主 营业务将新增预灌封给药系统及自动安全给药系统等医药包材业务。财务数据显示，标的公司2023年、 2024年及2025年1-9月（备考）的营业收入分别为14.30亿元、16.73亿元和14.12亿元，净利润分别为4.83 亿元、5.81亿元和4.86亿元。以2025年9月30日为评估基准日，标的资产采用收益法评估的增值率达 192.90%。交易对方承诺，威高普瑞2026—2028年承诺净利润分别为6.40亿元、7.20亿元、7.84亿元，若 交易实施延后至2027年，承诺期将相应调整为2027—2029年，对应承诺净利润分别为7.20亿元、7.84亿 元、8.45亿元。 ...

Core Viewpoint - Weigao Co., Ltd. is experiencing a decline in stock price following the announcement of a significant acquisition aimed at enhancing its business portfolio and profitability [1] Group 1: Acquisition Details - Weigao Co., Ltd. plans to acquire 100% equity of Weigao Purui from three parties for approximately 8.511 billion yuan [1] - Upon completion of the transaction, Weigao Purui will become a wholly-owned subsidiary, adding pharmaceutical packaging business to the company's main operations [1] Group 2: Market Position and Impact - Weigao Purui holds the largest market share in pre-filled products in China, exceeding 50% from 2022 to 2024, and ranks first in the domestic market [1] - The company is also among the top five in international sales within the industry [1] - The acquisition is expected to enhance the company's profitability and investment value by incorporating a high-quality asset into its consolidated financial statements [1]

消息面上，1月5日，威高血净（603014）发布公告，拟通过发行股份的方式购买威高股份、威海盛熙和 威海瑞明3名交易对方持有的威高普瑞100%股权，交易价格约为85.11亿元。交易完成后威高普瑞将成 为公司全资子公司，公司主营业务将新增医药包材相关业务。 公告显示，威高普瑞预灌封产品市占率居国内第一。根据中国医药包装协会出具的说明，2022年至2024 年，威高普瑞预灌封产品国内市场占比均超过50%，在国内市场行业中排名第一，在国际市场销量位列 行业前五。威高血净称，本次交易完成后，威高普瑞作为盈利能力较强的优质资产将纳入上市公司合并 报表范围，将进一步提高上市公司盈利能力和投资价值。 威高股份(01066)早盘跌超5%，截至发稿，跌4.91%，报5.04港元，成交额1846.65万港元。 ...

Core Viewpoint - Weigao Blood Purification plans to acquire 100% equity of Weigao Puri Pharmaceutical Packaging for an assessed value of 8.511 billion yuan, marking a significant asset restructuring and expanding its business into pharmaceutical packaging [2] Group 1: Acquisition Details - The acquisition will be fully paid through the issuance of shares, with Weigao Co. and its concerted parties increasing their stake in Weigao Blood Purification to 84.36%, maintaining absolute control [2] - Weigao Puri, established in 2018, specializes in pre-filled drug delivery systems and automatic safety drug delivery systems, aiming to provide comprehensive drug delivery solutions for global biopharmaceutical companies [2] Group 2: Financial Performance - As of June 30, 2025, Weigao Puri reported total assets of 3.425 billion yuan, total liabilities of 730 million yuan, and equity of 2.695 billion yuan, with a revenue of 939 million yuan and a net profit of 327 million yuan in the first half of 2025, indicating strong profitability [2] Group 3: Market Position - Weigao Puri has broken the overseas technology monopoly and holds a leading position in the domestic pre-filled product market, with over 50% market share from 2022 to 2024, ranking first domestically and among the top five internationally [3] Group 4: Strategic Rationale - The acquisition aims to diversify business operations and achieve technological synergy, allowing Weigao Blood Purification to leverage Weigao Puri's expertise in pharmaceutical packaging to expand its product line and reduce risks associated with a single business area [4] - The growing biopharmaceutical industry in China, projected to reach 534.8 billion yuan in 2024 and 1.13 trillion yuan by 2032, presents significant opportunities for both pharmaceutical packaging and upstream biopharmaceutical materials [4]